Rigel Pharmaceutical Inc. buy tamam
Start price
18.04.17
/
50%
€2.93
Target price
22.05.17
€3.61
Performance (%)
-21.85%
End price
22.05.17
€2.29
Summary
This prediction ended on 22.05.17 with a price of €2.29. The prediction for Rigel Pharmaceutical Inc. disappointed with a performance of -21.85%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Rigel Pharmaceutical Inc. | - | - | - | - |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
Comments by tamam for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rigel Pharmaceuticals (NASDAQ:RIGL) submits a New Drug Application
- to the FDA seeking approval of fostamatinib for the treatment of
patients with chronic and persistent immune thrombocytopenia (ITP), an Orphan Drug indication.
- Fostamatinib inhibits an enzyme called spleen tyrosine kinase (SYK) which plays a key role in certain blood cancers and autoimmune disorders.
(Vom Mitglied beendet)